explore -WSS

explore

author：fashion 2025-09-30 09:29:34 - browse：3343

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： 3 hurdles to bringing medical devices to the U.S. market

WSS

Ask STAT: What do you want to know about ChatGPT in medicine?

Do masks work? RCTs can't tell us

White House drug shortage group privately met with industry

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

The drug industry sees a key ally in the Senate prevail

explore

explore

entertainment

Activists slam private health insurers over coverage restrictions

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Apple is now the first public company to be valued at $3 trillion

Paxlovid study fails to answer questions over benefit for broader groups

How to save PrEP access — and even expand it

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

My superpower is killing ticks

In age of alternative facts, a scholarly course on calling out crap

What would happen to your eyes if you looked at the solar eclipse?

Wikipedia

Nearly two

For BCIs, commercial hurdles may be bigger than scientific ones

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

My superpower is killing ticks

CDC concerned about possible undetected monkeypox spread in U.K.

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

focus

focus

focus

hotspot